SCHEMBL6384266

SCHEMBL6384266

CC(C)(C)OC(=O)NC1CCN(CCCCl)CC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.54
CTSK P43235 2/20 0.49
DRD2 P14416 6/20 0.47
DRD3 P35462 2/20 0.47
CCR5 P51681 1/20 0.45
HRH2 P25021 2/20 0.43
HRH1 P35367 2/20 0.43
BTK Q06187 1/20 0.43
USP14 P54578 1/20 0.42
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42
SKP2 Q13309 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CYP2C9 P11712 1/20 0.42
HSD11B1 P28845 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26814105 0.92 KCNA3 (0.56) KCNA3CTSKDRD2DRD3CCR5
SCHEMBL23421609 0.87 KCNA3 (0.55) KCNA3CTSKDRD2DRD3CCR5
SCHEMBL3460701 0.87 KCNA3 (0.55) KCNA3CTSKDRD2DRD3CCR5
SCHEMBL4419007 0.87 KCNA3 (0.55) KCNA3CTSKDRD2DRD3CCR5
SCHEMBL9092293 0.86 KCNA3 (0.54) KCNA3CTSKDRD2DRD3CCR5
SCHEMBL24690239 0.86 KCNA3 (0.54) KCNA3CTSKDRD2DRD3CCR5
SCHEMBL30893341 0.85 KCNA3 (0.53) KCNA3CTSKDRD2DRD3CCR5
SCHEMBL28840007 0.85 KCNA3 (0.53) KCNA3CTSKDRD2DRD3CCR5
SCHEMBL26814329 0.85 KCNA3 (0.53) KCNA3CTSKDRD2DRD3CCR5
SCHEMBL26813557 0.85 KCNA3 (0.53) KCNA3CTSKDRD2DRD3CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4405359-A2 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-31 EP disclosed
WO-2023049790-A2 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-03-30 WO disclosed
EP-1012147-B1 O-SUBSTITUTED HYDROXYCUMARANONE DERIVATIVES AS ANTITUMOR AND ANTIMETASTATIC AGENTS HOFFMANN LA ROCHE (CH) 2005-11-02 EP disclosed
US-6200989-B1 ADMINISTERING AS UROKINASE PLASMINOGEN ACTIVATOR ANTAGONISTS, ANTITUMOR AND ANTIMETASTASIS AGENTS HOFFMANN-LA ROCHE INC. 2001-03-13 US disclosed